Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spare cancer patients unneeded iron infusions

NCT ID NCT03656172

Knowledge-focused Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RET-He levels before treatment and comparing them to hemoglobin levels one month later, researchers hope to refine iron prescription, giving iron only to those who truly need it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Measurement of reticulocyte hemoglobin content (RET-He) via blood test, used to guide iron treatment decisions
What this could lead to
If RET-He predicts iron response, doctors could personalize iron therapy for anemic cancer patients, avoiding unnecessary treatments.
What could go wrong
This is a small, early-stage study. The correlation may be weak, and results might not apply broadly to all cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

51 people

The number who actually took part.

Started

May 2017

Finished

May 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with anaemia treated at the ICO for a solid tumour, not treated or treated with chemotherapy and/or radiotherapy and/or surgery, having benefited before the inclusion of a blood test including an NFS, reticulocytes with RET-He , a martial blood test (iron, transferrin and Ferritin), a CRP, vitamins B12 and B9, a creatinine, a haptoglobin, a TSH.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Metastatic solid tumor or not. * Anemia by functional martial deficiency (as defined in the NCCN2016 recommendations): o Hb \< 11 g/DL, TSAT \< 20% and ferritinlike between 30 and 800 ng/ml * Initial assessment of anemia carried out at the laboratory of Biopathology of the ICO Exclusion Criteria: * Patient with malignant hemopathy. * Patient with chronic renal failure with an estimation of renal filtration rate according to the formula CKD-EPI \< 60 ml/min/1.73 m². * Patient with vitamin B12 deficiency, folate deficiency, hemolysis and/or hemoglobinopathy. * Patient with active infection. * Patient with bone marrow tumor. Confirmation by a osteo-medullary biopsy (BOM) or a myelogram is not necessary to exclude the patient. * Patient who received ASE within two months prior to the initial blood test. * Patient who received iron (oral or injectable) in the two months preceding the initial blood test. * Patient who received a transfusion of globular pellets in the month preceding the initial blood test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

deficiency anemia iron deficiency anemia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia deficiency Solid tumor, adult

Contacts and locations

Locations

  • Institut de Cancérologie de l'Ouest

    Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.